Dashboard

Madrigal Pharmaceuticals, Inc.

MDGLNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$13B

Price$544.5152w $272.67 – $602.83

Conviction4/ 5

Revenue (TTM)$1.1B

Revenue growth YoY+256.8%

P/E (trailing)—

Gross margin93.1%

Operating margin-27.7%

Net margin-27.3%

52w price change+99.7%

Next earningsJul 30, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Jul 20
Ownership changeSEC
Form 4 insider transaction filing
Jul 8
OtherClinicalTrials.gov
Phase 3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) for resmetirom in NASH cirrhosis status updated to ACTIVE_NOT_RECRUITING.
Jun 18
Ownership changeSEC
Form 4 insider transaction filing.
Jun 18
Ownership changeSEC
Form 4 insider transaction filing for MDGL.
Jun 18
Ownership changeSEC
SEC Form 4 insider transaction filing
Jun 18
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jun 18
Ownership changeSEC
Form 4 insider transaction filing
Jun 18
Ownership changeSEC
Form 4 insider transaction filing.
Jun 17
LeadershipSEC
8-K filed disclosing items 5.02 (officer/director matters), 5.07 (shareholder vote), 9.01 (exhibits).
Jun 16
Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).
Jun 4
Trial readoutClinicalTrials.gov
Phase 2 trial NCT03038022 (MGL-3196 in HeFH) status updated to COMPLETED
Jun 2
OtherClinicalTrials.gov
Phase 3 trial NCT05500222 (resmetirom, NASH cirrhosis) status updated to ACTIVE_NOT_RECRUITING
Jun 1
Ownership changeSEC
Form 4 insider filing reported.
Jun 1
OtherClinicalTrials.gov
Phase 3 trial NCT03900429 (resmetirom, NASH/fibrosis) status updated to ACTIVE_NOT_RECRUITING on 2026-06-01.
May 28
Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).
May 27
OtherClinicalTrials.gov
Phase 3 MAESTRO-NAFLD-OLE trial (NCT04951219) status updated to ACTIVE_NOT_RECRUITING
May 22
Ownership changeSEC
Form 4 insider transaction filing
May 18
Ownership changeSEC
SEC Form 4 insider transaction filing dated 2026-05-18.
May 6
Financial resultsSEC
Madrigal Pharmaceuticals filed 8-K (items 2.02,9.01) disclosing results of operations.

Not financial advice — research and opinion only. Disclosures